Spotlight
Specialty
Partners
CME/CE
How Many Lines of Therapy Are Patients Receiving for Urothelial Carcinoma?
A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.
EP: 1.Overview of Practice Patterns in Urothelial Carcinoma
Now Viewing
EP: 2.How Many Lines of Therapy Are Patients Receiving for Urothelial Carcinoma?
EP: 3.Novel Treatment Strategies in Non-Muscle Invasive Bladder Cancer
EP: 4.MIBC and mUC: Surgery, Systemic Therapy, and Bladder Preserving Treatments
EP: 5.Evolving Neoadjuvant Treatment Strategies in Muscle-Invasive Bladder Cancer
EP: 6.Adjuvant Treatment Approaches in Muscle-Invasive Bladder Cancer
EP: 7.Muscle-Invasive Bladder Cancer: Role of Minimal Residual Disease in Adjuvant Therapy
EP: 8.Clinical Trial Data With Perioperative Therapy in MIBC: The RETAIN BLADDER Study
EP: 9.Clinical Trial Data With Perioperative Therapy in MIBC: HCRN GU 16-257
EP: 10.Clinical Trial Data With Perioperative Therapy in MIBC: Bladder BRIDGister
EP: 11.Novel Treatment Strategies in Muscle Invasive Bladder Cancer
EP: 12.First-Line Treatment Options for Patients With Metastatic Urothelial Carcinoma
EP: 13.Metastatic Urothelial Carcinoma: Number of Frontline Chemotherapy Cycles
EP: 14.Goals of Maintenance Therapy in Metastatic Urothelial Carcinoma
EP: 15.Real-World Data With Avelumab Maintenance Therapy in Metastatic Urothelial Carcinoma
EP: 16.Metastatic Urothelial Carcinoma: Intensifying Maintenance Immunotherapy
EP: 17.Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma
EP: 18.Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape
Related Videos
Related Content
